This approval adds to Granules India's existing 67 ANDA approvals from the US FDA, strengthening its position in regulated ...

Before arriving at the ED, the patient had been initiated on a course of bupropion and transdermal nicotine (21 mg/24 hr) for smoking cessation. He had received bupropion hydrochloride extended ...

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) ...

Seizures associated with pediatric single-substance exposures are steadily increasing, according to a study presented at the ...

Bupropion hydrochloride extended-release tablets are widely prescribed for the treatment of major depressive disorder and for ...

Granules India's US subsidiary receives FDA approval for generic Bupropion Hydrochloride Extended-Release Tablets, expanding ...

Granules India has received USFDA approval to market a generic medication for major depressive disorder, Bupropion ...

The abbreviated new drug application (ANDA) for the product was filed with the USFDA by Granules Pharmaceuticals, Inc. (GPI), ...

"Seizure is one of the most severe symptoms a poisoned patient can experience, and children are particularly vulnerable," a ...

Granules Pharmaceuticals, Inc., a 100% foreign subsidiary of Granules India received the U.S. Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA) of Bupropion ...